Form 8-K - Current report:
SEC Accession No. 0001193125-23-077853
Filing Date
2023-03-23
Accepted
2023-03-23 16:05:54
Documents
14
Period of Report
2023-03-23
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d471634d8k.htm   iXBRL 8-K 25530
2 EX-99.1 d471634dex991.htm EX-99.1 94308
6 GRAPHIC g471634g94j84.jpg GRAPHIC 10347
  Complete submission text file 0001193125-23-077853.txt   274010

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA eq-20230323.xsd EX-101.SCH 2848
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE eq-20230323_lab.xml EX-101.LAB 18738
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE eq-20230323_pre.xml EX-101.PRE 11708
8 EXTRACTED XBRL INSTANCE DOCUMENT d471634d8k_htm.xml XML 3463
Mailing Address 2223 AVENIDA DE LA PLAYA SUITE 105 LA JOLLA CA 92037
Business Address 2223 AVENIDA DE LA PLAYA SUITE 105 LA JOLLA CA 92037 (858) 412-5302
Equillium, Inc. (Filer) CIK: 0001746466 (see all company filings)

EIN.: 821554746 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38692 | Film No.: 23756218
SIC: 2834 Pharmaceutical Preparations